Table 4.
Relationship between ING3 mRNA expression and clinicopathological characteristics
| Characteristic | ING3 mRNA expression | p53 status | ||||
|---|---|---|---|---|---|---|
| Low (%) n = 37 (52.1) | Normal to high (%) n = 34 (47.9) | P‐value | Mutant (%) n = 28 (41.0) | Wild type (%) n = 41 (59.0) | P‐value | |
| Predictor | ||||||
| Sex ‡ | ||||||
| Male | 32 (86.5) | 29 (85.3) | 0.88 | 25 (89.3) | 35 (85.4) | 0.44 |
| Female | 5 (13.5) | 5 (14.7) | 3 (10.7) | 6 (14.6) | ||
| Age § | ||||||
| Mean ± SD (years) | 64.70 ± 8.9 | 64.0 ± 8.6 | 0.73 | 64.7 ± 7.5 | 64.3 ± 9.5 | 0.86 |
| Smoking ‡ | ||||||
| Yes | 29 (78.4) | 23 (67.6) | 0.31 | 23 (82.1) | 27 (65.9) | 0.14 |
| No | 8 (21.6) | 11 (32.4) | 5 (17.9) | 14 (34.1) | ||
| Alcohol consumption ‡ , ¶ | ||||||
| Yes | 22 (61.1) | 18 (54.5) | 0.58 | 17 (63.0) | 21 (52.5) | 0.40 |
| No | 14 (38.9) | 15 (45.5) | 10 (37.0) | 19 (47.5) | ||
| TNM stage † , ‡ | ||||||
| Early stage (I–II) | 7 (18.9) | 11 (32.4) | 0.19 | 6 (21.4) | 11 (26.8) | 0.61 |
| Late stage (III–IV) | 30 (81.1) | 23 (67.6) | 22 (78.6) | 30 (73.2) | ||
| Tumor stage † , ‡ | ||||||
| Early T (T1–T2) | 12 (32.4) | 17 (50.0) | 0.13 | 11 (39.3) | 16 (39.0) | 0.98 |
| Late T (T3–T4) | 25 (67.6) | 17 (50.0) | 17 (60.7) | 25 (61.0) | ||
| Nodal stage ‡ | ||||||
| N (0) | 16 (43.2) | 16 (47.1) | 0.75 | 11 (39.3) | 20 (48.8) | 0.44 |
| N (+) | 21 (56.8) | 18 (52.9) | 17 (60.7) | 21 (51.2) | ||
| p53 status ‡ | ||||||
| Wild type | 22 (61.8) | 19 (55.9) | 0.55 | – | – | |
| Mutated | 13 (38.2) | 15 (44.1) | – | – | ||
| Differentiation ‡ , ¶ | ||||||
| Well | 14 (37.8) | 6 (19.4) | 0.10 | 6 (23.1) | 14 (34.1) | 0.33 |
| Moderate to poor | 23 (62.2) | 25 (80.6) | 20 (76.9) | 27 (65.9) | ||
| Radiation therapy ‡ | ||||||
| Performed | 18 (48.6) | 19 (55.9) | 0.54 | 14 (50.0) | 19 (46.3) | 0.76 |
| Not performed | 19 (51.4) | 15 (47.1) | 14 (50.0) | 22 (53.7) | ||
| Chemotherapy ‡ | ||||||
| Performed | 14 (37.8) | 11 (32.4) | 0.63 | 10 (35.7) | 14 (34.1) | 0.89 |
| Not performed | 23 (62.2) | 23 (67.6) | 18 (64.3) | 27 (65.9) | ||
| Previous cancer history ‡ , ¶ | ||||||
| Exist | 5 (14.3) | 7 (22.6) | 0.38 | 7 (25.9) | 4 (10.8) | 0.12 |
| Not exist | 30 (85.7) | 24 (77.4) | 20 (74.1) | 33 (89.2) | ||
| Location ‡ | ||||||
| Oral cavity | 17 (46.0) | 14 (41.2) | 0.90 | 8 (28.5) | 21 (51.2) | 0.40 |
| Oropharynx | 6 (16.2) | 3 (08.8) | 4 (14.3) | 5 (12.2) | ||
| Larynx | 6 (16.2) | 7 (20.6) | 7 (25.0) | 6 (14.6) | ||
| Maxilla | 3 (8.1) | 4 (11.8) | 4 (14.3) | 3 (7.4) | ||
| Hypopharynx | 5 (13.5) | 6 (17.6) | 5 (17.9) | 6 (14.6) | ||
†
According to the International Union Against Cancer 1997 TNM classification system.
‡
χ2‐test.
§
Student's t‐test.
¶
¶ The cases with unknown situation for alcohol consumption (2), p53 mutation status (2), differentiation (3), and previous cancer history (5) were not included for evaluation.